LONDON – Actelion Ltd. added the European Medicines Agency’s (EMA) nod for Opsumit (macitentan) in treating pulmonary arterial hypertension (PAH) to FDA approval received at the end of last week. (See BioWorld Today, Oct. 21, 2013.)